Tyler Curiel

Dr. Tyler Curiel, M.D. MPH is a physician-scientist with clinical expertise in phase I experimental therapeutics and gynecologic cancers. Graduating summa cum laude with the highest honors and honors in chemistry from the University of Georgia. He received his MD degree from Duke Medical School and his MPH from Harvard University. He did his internal medicine internship and residency at Yale-New Haven Hospital and Yale Medical School and a fellowship in infectious diseases at Massachusetts General Hospital and Harvard Medical School. He later re-trained as a medical oncologist at the University of Colorado. He is currently certified by the American Board of Internal Medicine in internal medicine, infectious diseases, and medical oncology.

His laboratory group focuses on developing effective immunotherapies for cancer, autoimmunity, and age-related diseases. In the past 15 years, his group has made important observations in the immunopathogenesis of ovarian cancer, including demonstrating a pivotal role for regulatory T cells and B7-H1 immune co-signaling, with the goal of developing more effective immunotherapies. These concepts have been put into ovarian cancer clinical trials with some successes, but his group continually seeks to improve clinical responses with novel approaches by changing paradigms within these therapies,

He has significant administrative expertise as past chief of two different academic divisions of hematology and medical oncology, director of a general clinical research center, and executive director of an NCI-designated cancer center. He was recently awarded a grant by the National Institute of Health to continue his cancer research.